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Using a model for performance of penicillamine (PCA) anti-cancer drug on selenium-cyclic peptide nanoparticle 
(CPSeNP), 11 noncovalent configurations have been investigated. Se8 ring model and cyclooctaglycine have been used for 
selenium nanoparticle (SeNP) and cyclic peptide (CP), respectively. Binding energies, quantum molecular descriptors and 
solvation energies have been studied in gas phase and water at M06-2X /6-31G** level of theory. The calculated energies 
represent the high-energy stability of CPSeNP/PCA 1-11 configurations. Solvation energies showed that drug solubility 
increases, which is a major factor for their use in drug delivery. Regarding to quantum molecular descriptors such as 
hardness and electrophilic power, the drug reactivity increases in the vicinity of SeNP. The QTAIM analysis revealed that 
intramolecular interaction Se-L (L =O, H , S, C , N) plays an important role in the system. Se-L interaction in all 
configurations is relevant to weak interactions. The configurations that PCA drug is located in parallel with the carrier 
(CPSeNP) are more stable than penicillamine-CP or penicillamine-SeNP systems. 
Keywords: Selenium nanoparticle, Cyclic peptide, Penicillamine, Drug delivery, Density Functional Theory (DFT) 
Effective delivery of drug toward target sites will 
significantly improve their therapeutic effectiveness. 
Drug delivery systems have been recently mentioned 
as new tools for improving drug efficacy1,2. Iron oxide 
NPs3, Silica NP4, Gold NPs5 and other mineral NPs6 
have been studied to reduce toxicity and increase 
biocompatibility and stability. Nanoscientists use a 
broad range of biomedical applications of nanoparticles, 
with regard to their chemical stability, environmental 
compatibility, high mechanical resistance and strength 
to bacterial attacks7–9. 
Cyclic peptide have many applications in different 
fields such as drug delivery, nanoscience, optical 
sensors, and electronic devices10–13. The cyclic structure 
of these compounds with various chain amino acids is 
a good model for encapsulation of drugs14. Cyclic 
structure is made by the terminus of a peptide attached 
to another part of the peptide with an amide bond. In 
comparison to synthetic molecules, peptides have less 
toxicity, so they don’t aggregate in the tissue. Drugs 
based on cyclic peptides can be less harmful. Due to 
the higher stability of configuration, the cyclic peptides 
have usually better biological activities in comparison 
to similar types of linear peptides. 
Cyclic peptides have various structural features  
that allow them to be used as connectors of target  
drugs in medical applications. The studies showed that 
intracellular adsorption can be impressively enhanced 
in the presence of cyclic peptide containing arginine 
and tryptophan15–17. Penicillamine is used for genetic 
disorder related to cooper metabolism (Wilson 
disease)18,19. In addition, it is used as an anticancer 
factor. Recent studies have shown the inhibition of the 
growth of various cancerous cells20. The thiol group 
exhibits high permeability to cancerous cells due to its 
high reactivity in its structure and has a high rate in 
removal of cancerous cells and can strongly connect to 
blood protein for delivery of penicillamine into 
cancerous cells20,21. It has been reported that poly(α)-L-
glutamic acid PCA (PGA-PCA) system, increases the 
permeability of penicillamine into cancerous cells22,23. 
The potential application of nanotechnology in the 
development of new drug delivery systems (DDSs) is 
under consideration24–26. Drug delivery systems based 
on nano-DDS have several advantages over larger 
DDSs, such as lower toxicity and improved cellular 
absorption. Peptides are commonly used as nano-scale 
systems for drug delivery, due to their ability to carry a 
wide range of molecules through the encapsulation of 
the drug. In addition, peptides are used as a part of the 
nanoscale structure DDS by a wide range of amino 
acids with different physio-chemical properties. For 
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example, functionalized peptides with gold 
nanoparticles have been used as one of the previous 
biochemical systems for drug delivery and the 
improvement of cellular delivery of several drugs by 
noncovalent complexation17,27,28. Among various metal 
nanoparticles, selenium nanoparticles (SeNPs) have not 
been studied very much. Selenium is a necessary 
element that is daily absorbed from the diet (55 μg). 
Also, selenium is essential for cellular function. A high 
dose of selenium can cause cell death29. So, new 
functionalized SeNPs are needed which can be used as 
non-toxic nano DDS30. Functionalized SeNPs with 
other compounds improve their biological properties. 
The size of nanoparticles is a critical factor that can 
change their biological activity. The consumption and 
selenium chemical composition is very important for 
reducing toxicity and increasing therapeutic effects31,32. 
Quantum studies help to design and analysis of 
drug delivery systems33–36. The Nobel Prize for 
Chemistry awarded in 2016 was given for the design 
and manufacture of usable molecular machines in 
drug delivery37,38. In addition to the experimental 
methods, the quantum chemical methods are 
important tools for the investigation of drug carrier 
systems39–45. In this study, density functional theory 
(DFT) was utilized to investigate the functionalization 
of cyclic peptide-selenium nanoparticles (CPSeNPs) 
using penicillamine (PCA) anticancer drug. 
 
Computational methods 
DFT calculations are performed using M06-2X46,47 
with Gaussian 0948 and 6-31G(d,p) basis set. All 
species have been optimized in gas phase and water. 
Solvent effects were studied using the (PCM)49,50 
model. Solvation energies (ΔEsolv) were calculated 
using the following equation. 
∆𝐸௦௢௟௩ ൌ 𝐸௦௢௟ െ 𝐸௚௔௦ …(1) 
 
Where Esol and Egas represent the total energy of 
solution and gas phase, respectively. 
Calculations were performed for penicillamine, 
cyclic peptide (CP), selenium nanoparticles (SeNPs) 
systems. Quantum molecular descriptors were used to 
investigate chemical reactivity and stability. The 
hardness (η) shows the resistance versus the 
electronic structure change.  
 
η ൌ ሺI െ Aሻ/2 …(2) 
 
Where I = –EHOMO, A = –ELUMO.  
The electrophilicity index (𝜔)51 was obtained from 
equation (3): 
 
𝜔 ൌ ሺ𝐼 ൅ 𝐴ሻଶ/8η …(3) 
 
We investigated the hydrogen bond using the 
QTAIMs calculations. QTAIM calculations are done 
by the AIMALL software52. QTAIM is based on 
topological parameters such as electron density ρ (r)53. 
We studied various values of electron density such as 
Gb (kinetic energy density), Vb (potential energy 
density), Hb (total energy density), and ∇2ρ (Laplacian 
of electron density) at a critical point (BCP) to 
distinguish the nature of the bond in different species. 
 
Results and Discussion 
Binding and solvation energies 
Cyclooctaglycine and Se8 ring model were 
employed for cyclic peptide (CP)54 and selenium 
nanoparticle (SeNP)55,56, respectively. Selenium 
nanoparticle, cyclic peptide and penicillamine drug 
including SH, OH, CO, NH2 groups are shown in  
Fig. 1. The interaction of penicillamine with peptide-
  
Fig. 1 ― Optimized structures of PCA, SeNP, CP, SeNP/PCA and CP/PCA. 
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selenium nanoparticles has been considered in 11 
different ways (CPSeNP/ PCA1–11). The optimized 
geometries of CPSeNP/ PCA1–11 in aqueous solution 
at the M06-2X/6-31G ** level are shown in the  
Fig. 2 (see the Supplementary data for the Cartesian 
coordinates and absolute energies of the calculated 
structures). 
Binding energies (ΔE) were calculated using the 
following equation: 
 
∆𝐸 ൌ 𝐸஼௉ௌ௘ே௉/௉஼஺ଵିଵଵ െ ሺ𝐸஼௉ ൅ 𝐸ௌ௘ே௉ ൅ 𝐸௉஼஺ሻ …(4) 
 
Where 𝐸஼௉ௌ௘ே௉/௉஼஺ଵିଵଵ, 𝐸஼௉, 𝐸ௌ௘ே௉ and 𝐸௉஼஺ are 
energies of CPSeNP/ PCA1-11, CP, SeNP and PCA, 
respectively. 
Fig. 2 ― Optimized structures of CPSeNP/PCA1-11. 
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The binding energy values in gas phase and water 
in M06-2X are shown in Table 1. ΔEs depend on the 
orientation of the drug relative to the CPSeNP. 
According to both phases, among 11 species, 
CPSeNP/ PCA4 is the most stable chemical structure 
in which the penicillamine drug stay on in parallel 
with CPSeNP, and the OH and SH functional groups 
interact with the functional groups of CPSeNP and the 
OH bonding is kind of hydrogen bonding (Fig. 2). 
Comparison of binding energies shows that the 
encapsulation of SeNP within the CP increases the 
binding energy, therefore, PCA can be functionalized 
on the CPSeNP surface, although this performance is 
sometimes weaker in aqueous solutions than in the 
gas phase.  
We evaluated the solvation energies for all species 
(Table 1). The negative values of these energies 
indicate that the solvation process is spontaneous. The 
absorption of PCA drug on CPSeNP increases drug 
solubility, which is an essential factor for its 
application as an efficient anti-cancer drug. 
The drug solubility in the presence of CPSeNP 
increases from –31.34 kJ mol–1 to –99.43 kJ mol–1 
(mean value of CPSeNP/PCA1–11). The solubility of 
SeNP increases after activating CPSeNP with PCA 
medicine, which is very important in drug delivery 
field. The major reason of increasing PCA and SeNP 
solubility is the presence of CP. 
SeNP solubility increased from –9.66 kJ mol–1 to  
–99.43 kJ mol–1 (mean value of CPSeNP/PCA1–11) 
in the vicinity of CP and PCA. Due to having CO, NH 
functional groups, CP causes a hydrogen bond 
between the PCA drug and CP and the solubility of 
the CP decreases somewhat. 
Therefore, CP in addition to decreasing SeNP 
toxicity, increases its solubility, which is an important 
problem in drugs targeted delivery. In fact, these two 
carriers of CP and SeNP complement each other, and 
the presence of SeNP improves the binding energy 
values and CP solubility. 
 
Quantum molecular descriptors 
In quantum molecular descriptors (both gas phase 
and water), the Eg (energy gap between LUMO and 
HOMO) and η values of CPSeNP/PCA1–11 are 
approximately the same, as shown in Table 2. Eg and 
η values of structure 4 are more than other structures, 
 
Table1 ― Binding and solvation energy values (𝑘𝐽𝑚𝑜𝑙ିଵ) for 
corresponding structures 
Species ∆𝐸gas ∆𝐸ுమை ∆𝐸௦௢௟௩ 
PCA – – –31.34 
CP – – –140.53 
SeNP – – –9.66 
CP/PCA –219.86 –113.44 –17.15 
SeNP/PCA –79.53 –75.52 –36.99 
CPSeNP/PCA1 –503.80 –464.26 –84.03 
CPSeNP/ PCA2 –457.63 –445.79 –111.74 
CPSeNP/ PCA3 –482.54 –470.13 –111.15 
CPSeNP/ PCA4 –547.60 –497.19 –73.17 
CPSeNP/ PCA5 –514.59 –494.86 –103.83 
CPSeNP/ PCA6 –473.85 –461.30 –111.01 
CPSeNP/ PCA7 –496.95 –470.94 –97.56 
CPSeNP/ PCA8 –485.08 –462.11 –100.60 
CPSeNP/ PCA9 –511.93 –494.66 –106.31 
CPSeNP/PCA10 –523.83 –495.94 –95.68 
CPSeNP/PCA11 –487.92 –463.04 –98.69 
 
 
Table 2 ― Quantum molecular descriptors (eV) for optimized 
geometries 
Species EHOMO ELUMO Eg  
H2O 
Se –1.64 –7.18 5.54 2.77 3.51 
PCA 1.21 –8.16 9.37 4.68 1.28 
CP 1.39 –8.49 9.89 4.94 1.27 
CP/PCA 0.99 –7.99 8.99 4.49 1.36 
NP/ PCA –1.59 –7.09 5.50 2.75 3.43 
CP–SeNPs/ PCA1 –1.29 –6.84 5.55 2.77 2.97 
CP–SeNPs/ PCA2 –1.47 –6.95 5.47 2.73 3.23 
CP–SeNPs/ PCA3 –1.48 –6.87 5.39 2.69 3.24 
CP–SeNPs/ PCA4 –1.36 –6.91 5.54 2.77 3.08 
CP–SeNPs/ PCA5 –1.34 –6.86 5.51 2.75 3.05 
CP–SeNPs/ PCA6 –1.47 –6.91 5.44 2.72 3.23 
CP–SeNPs/ PCA7 –1.39 –6.82 5.42 2.71 3.11 
CP–SeNPs/ PCA8 –1.42 –6.86 5.43 2.71 3.15 
CP–SeNPs/ PCA9 –1.42 –6.83 5.40 2.70 3.14 
CP–SeNPs/ PCA10 –1.47 –6.91 5.43 2.71 3.24 
CP–SeNPs/ PCA11 –1.37 –6.88 5.51 2.75 3.09 
Gas 
Se –1.74 –7.23 5.49 2.74 3.66 
PCA 1.34 –8.02 9.36 4.68 1.18 
CP 1.34 –8.57 9.91 4.9 1.31 
CP/ PCA 0.84 –8.03 8.88 4.44 1.45 
SeNP/ PCA –1.58 –7.04 5.46 2.73 3.40 
CP–SeNPs/ PCA1 –1.22 –6.74 5.52 2.76 2.87 
CP–SeNPs/ PCA2 –1.53 –6.95 5.41 2.70 3.32 
CP–SeNPs/ PCA3 –1.56 –6.89 5.32 2.66 3.35 
CP–SeNPs/ PCA4 –1.28 –6.82 5.53 2.76 2.96 
CP–SeNPs/ PCA5 –1.36 –6.84 5.47 2.73 3.07 
CP–SeNPs/ PCA6 –1.59 –6.98 5.38 2.69 3.41 
CP–SeNPs/ PCA7 –1.49 –6.85 5.35 2.67 3.25 
CP–SeNPs/ PCA8 –1.47 –6.87 5.39 2.69 3.23 
CP–SeNPs/ PCA9 –1.50 –6.85 5.35 2.67 3.25 
CP–SeNPs/ PCA10 –1.49 –6.85 5.36 2.68 3.25 
CP–SeNPs/ PCA11 –1.41 –6.90 5.48 2.74 3.15 
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which indicates that it is more stable than other 
structures. Eg , η and I for the drug are greater than 
those of the CPSeNP/PCA1-11 configurations, which 
indicates that drug stability in the presence of 
selenium and cyclic peptide is reduced and its 
reactivity is increased. 
Since electrophilicity is used to predict toxicity, it 
can be said that the toxicity of SeNP is reduced in the 
presence of the cyclic peptide and drug. The ω values 
of CPSeNP/PCA1-11 are higher than PCA in both 
phases, which indicates that the PCA drug plays the 
role of the electron acceptor. 
 
QTAIM analysis 
In this section, a comprehensive study about the 
nature and bonding interactions strength was 
performed by analyzing critical points of BCP 
bonding using QTAIM analysis. One of the 
parameters is electron density (ρ(r)), which indicates 
the strength of a bond, if the amount of ρ(r) to be 
large, means that the related bond is stronger. 
Laplacian electron density (∇2ρ) shows the nature of 
bond. The positive value of ∇2ρ indicates a decrease 
in electron density for the closed-shell systems such 
as ion interactions, hydrogen bond and Van der Waals 
interactions. In contrast to the negative values of  
∇2ρ indicate that the electron density is focused in the 
internuclear region (shared interactions or covalent 
interactions). 
If (∇2ρ <0, Hb <0), (∇2 ρ> 0, Hb <0) and (∇2ρ> 0, 
Hb> 0), interactions will be strong, intermediate and 
weak, respectively. For the parameter -Gb/Vb, if  
-Gb/Vb>1, 0.5<-Gb/Vb<1 and -Gb/Vb<0.5, the 
character of a bond will be non-covalent, partially 
covalent, and covalent bonds, respectively57.  
The structures of CPSeNP/PCA4 and CPSeNP/ 
PCA2 have been reported as the most stable 
configuration and the most unstable configuration, 
respectively. The molecular graph for CPSeNP/PCA4 
configuration in aqueous solution is shown in Fig. 3. 
The values of -Gb/Vb, Vb, Gb, Hb, ∇2ρ (r), ρ (r) are 
shown in Table 3. The hydrogen bond energy values 
are calculated using EHB = 1 /2Vb58. Se-Se interactions 
in SeNP with ∇2ρ<0 , -Gb/Vb<0.5, Hb<0 are classified 
as strong covalent bonds (Table 3). 
In the configuration of CPSeNP/PCA4, we face 
with two categories of important interactions. The 
first group of interactions is related to SeNP-CP or 
SeNP-PCA (Se-L; L = O, N, C, S, H) drug. The 
interactions of Se-L with ∇2ρ>0, -Gb/Vb<1, Hb> 0 are 
related to weak interactions (Table 3). In the most 
stable configuration, the number and strength of these 
 Fig. 3 ― QTAIM Molecular graph of CPSeNP/PCA4. 
 
  
Table 3 ― Topological parameters in a.u. for CPSeNP/PCA4 
Atoms ρ(r) ∇ଶρሺrሻ 𝑉௕ 𝐺௕ 𝐻௕ −𝐺௕/𝑉௕ 
Se–Se interactions 
Se62 – Se63 0.0951 –0.038659 –0.0736 0.0319 –0.0416 0.43436 
Se60 – Se63 0.0161 0.043815 –0.0087 0.0098 0.0011 1.1279 
Se57 – Se60 0.0150 0.038784 –0.0076 0.0086 0.0010 1.1309 
Se57 – Se58 0.1108 –0.060533 –0.0993 0.0420 –0.0572 0.4238 
Se57 – Se64 0.1042 –0.05401 –0.0872 0.0368 0.0009 0.4226 
Se61 – Se64 0.0179 0.045099 –0.0094 0.0103 –0.0596 1.0960 
Se58 – Se59 0.1018 –0.051119 –0.0834 0.0353 –0.0480 0.4233 
Se60 – Se61 0.1062 –0.069832 –0.0874 0.0349 –0.0524 0.4001 
Se59 – Se60 0.1128 –0.07667 –0.1000 0.0404 –0.0596 0.4042 
Se58 – Se61 0.0164 0.043533 –0.0086 0.0097 0.0011 1.1266 
Se61 – Se62 0.1114 –0.073299 –0.0985 0.0400 –0.0584 0.4069 
(Contd.)
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interactions is higher. The CPSeNP/PCA4 species is 
included 23 interactions Se-L with ρav = 0.0125 and 
∇2 ρav = 0.038138. 
The second group of non-bonded interactions 
between CP and PCA is investigated through 
hydrogen bond. The interaction of H28 ⋯ O68 with 
∇2ρ>0, 𝐸ு஻ ൌ  െ 12.82 kJ molିଵ , Hb <0 , 0.5 <-Gb /Vb <1 is related to the medium hydrogen bond  
(Fig. 3 and Table 3). Four other hydrogen bonds  
are weak. 
The CPSeNP/PCA2 structure is the most unstable 
configuration. The molecular graph and values of  
-Gb/Vb, ρ (r), Vb , Gb , Hb, ∇2 ρ (r) have been 
presented in Fig. 4 and Table 4, respectively. Similar 
to CPSeNP/PCA4, Se-L interactions with Hb>0,  
-Gb/Vb>, ∇ଶρ ൐ 0 related to weak interactions. 
CPSeNP/PCA10 include 29 Se-L interactions with  
ρav = 0.0117 and ∇ଶρ௔௩ ൌ 0.0365. The interactions between PCA and CP have been investigated through 
hydrogen bond. The interaction of H75 ⋯ O21 with 
𝐻௕ ൏ 0 0.5, EHB = -55.29 kJ mol -1, ∇2ρ> 0, -Gb /Vb <1 is related to the medium hydrogen bond and one other 
hydrogen bond is weak (Table 4, Fig. 4). 
 
Table 3 ― Topological parameters in a.u. for CPSeNP/PCA4 (Contd.) 
Atoms ρ(r) ∇ଶρሺrሻ 𝑉௕ 𝐺௕ 𝐻௕ −𝐺௕/𝑉௕ 
Se–L interactions 
N11 – Se57 0.0126 0.0386 –0.0073 0.0085 0.0011 1.1590 
N14 – Se57 0.0116 0.0333 –0.0070 0.0076 0.0006 1.0918 
N17 – Se58 0.0142 0.0401 –0.0086 0.0093 0.0006 1.0788 
C6 – Se63 0.0144 0.0521 –0.0093 0.0111 0.0018 1.19869 
N8 – Se63 0.0089 0.0237 –0.0051 0.0055 0.0004 1.0809 
N2 – Se63 0.0126 0.0362 –0.0073 0.0082 0.0008 1.1150 
Se57 – Se64 0.1042 –0.0540 –0.0872 0.0368 –0.0503 0.4226 
O19 – Se57 0.0101 0.0317 –0.0060 0.0070 0.0009 1.1502 
H38 – Se58 0.0112 0.0350 –0.0060 0.0074 0.0013 1.2230 
H45 – Se58 0.0108 0.0324 –0.0056 0.0068 0.0012 1.2194 
H26 – Se59 0.0148 0.0374 –0.0086 0.0090 0.0003 1.0416 
H42 – Se60 0.0116 0.0366 –0.0065 0.0078 0.0013 1.2012 
O23 – Se60 0.0191 0.0624 –0.0142 0.0149 0.0006 1.0460 
O49 – Se61 0.0146 0.0482 –0.0103 0.0111 0.0008 1.0847 
H31 – Se62 0.0101 0.0323 –0.0051 0.0066 0.0014 1.2853 
O21 – Se62 0.0144 0.0453 –0.0099 0.0106 0.0006 1.0681 
H54 – Se62 0.0110 0.0343 –0.0060 0.0073 0.0012 1.2090 
O19 – Se64 0.0152 0.0484 –0.0108 0.0114 0.0006 1.0595 
Se57 – O68 0.0138 0.0434 –0.0094 0.0101 0.0007 1.0740 
Se64 – H84 0.0124 0.0358 –0.0068 0.0079 0.0010 1.1521 
Intermolecular hydrogen bonds 
O19 – H74 0.0053 0.0202 –0.0034 0.0042 0.0008 1.2409 
H41 – O68 0.0063 0.0231 –0.0041 0.0049 0.0007 1.1902 
H28 – O68 0.0122 0.0389 –0.0097 0.0097 –1.8E–05 0.9981 
O24 – H78 0.0122 0.0487 –0.0089 0.0105 0.0016 1.1842 
O56 – H84 0.0059 0.0226 –0.0037 0.0047 0.0009 1.2517 
 
 
 
 Fig. 4 ― QTAIM Molecular graph of CPSeNP/PCA2. 
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Conclusions 
Eleven peptide-selenium nanoparticles CPSeNP 
have been investigated with PCA anti-cancer drug at 
M06-2X level of theory in gas phase and water. It was 
used for cyclic peptide and selenium nanoparticles 
from cyclooctaglycine and Se8 ring model, 
respectively. The binding energy values indicate that 
the CPSeNP/PCA4 function is more appropriate and 
the interaction between drug-CP and SeNP leads to 
more stability. Solvation energies and quantum 
molecular descriptors show that PCA and SeNP 
solubility increases in the presence of CP and PCA 
reactivity increases in the vicinity of CPSeNP. Also, 
according to the QTAIM studies, PCA can be 
absorbed on CPSeNP via hydrogen bonding and Se-L 
interactions (Se-L; L = O, N, C, S, H). Se-L 
interactions and most hydrogen bonds are related to 
weak interactions ( ∇ଶρ ൐ 0, 𝐻௕ ൐ 0 and −𝐺௕/𝑉௕> 1).  
 
Table 4 ― Topological parameters in a.u. for CPSeNP/PCA2 
Atoms ρ(r) ∇ଶρሺrሻ 𝑉௕ 𝐺௕ 𝐻௕ −𝐺௕/𝑉௕ 
Se–Se interactions 
Se62 – Se63 0.0951 –0.0386 –0.0736 0.0319 –0.0416 0.4343 
Se60 – Se63 0.0161 0.0438 –0.0087 0.0098 0.0011 1.1279 
Se57 – Se60 0.0150 0.0387 –0.0076 0.0086 0.0010 1.1309 
Se57 – Se58 0.1108 –0.0605 –0.0993 0.0420 –0.0572 0.4238 
Se57 – Se64 0.1042 –0.0540 –0.0872 0.0368 –0.0503 0.4226 
Se61 – Se64 0.0179 0.0450 –0.0094 0.0103 0.0009 1.0960 
Se58 – Se59 0.1018 –0.0511 –0.0834 0.0353 –0.0480 0.4233 
Se60 – Se61 0.1062 –0.0698 –0.0874 0.0349 –0.0524 0.4001 
Se59 – Se60 0.1128 –0.0766 –0.1000 0.0404 –0.0596 0.4042 
Se58 – Se61 0.0164 0.0435 –0.0086 0.0097 0.0011 1.1266 
Se61 – Se62 0.1114 –0.0732 –0.0985 0.0400 –0.0584 0.4069 
Se–L interactions 
N11 – Se57 0.0126 0.0386 –0.0073 0.0085 0.0011 1.1590 
N14 – Se57 0.0116 0.0333 –0.0070 0.0076 0.0006 1.0918 
N17 – Se58 0.0142 0.0401 –0.0086 0.0093 0.0006 1.0788 
C6 – Se63 0.0144 0.0521 –0.0093 0.0111 0.0018 1.1986 
N8 – Se63 0.0089 0.0237 –0.0051 0.0055 0.0004 1.0809 
N2 – Se63 0.0126 0.0362 –0.0073 0.0082 0.0008 1.1150 
H41 – Se57 0.0085 0.0293 –0.0045 0.0059 0.0013 1.2978 
N44 – Se64 0.0117 0.0368 –0.0064 0.0078 0.0013 1.2102 
N53 – Se62 0.0090 0.0250 –0.0049 0.0055 0.0006 1.1333 
O22 – Se58 0.0131 0.0441 –0.0081 0.0096 0.0014 1.1751 
H45 – Se58 0.0133 0.0398 –0.0074 0.0087 0.0012 1.1642 
H26 – Se59 0.0144 0.0382 –0.0083 0.0089 0.0005 1.0689 
H42 – Se60 0.0124 0.0399 –0.0071 0.0085 0.0014 1.1993 
O23 – Se60 0.0197 0.0656 –0.0148 0.0156 0.0007 1.0530 
O49 – Se61 0.0151 0.0485 –0.0105 0.0113 0.0008 1.0760 
H31 – Se62 0.0114 0.0383 –0.0060 0.0078 0.0017 1.2854 
N2 – Se62 0.0098 0.0329 –0.0062 0.0072 0.0010 1.1609 
O21 – Se62 0.0110 0.0367 –0.0071 0.0081 0.0010 1.1424 
O56 – Se63 0.0101 0.0307 –0.0060 0.0068 0.0007 1.1304 
Se62 – O71 0.0083 0.0241 –0.0049 0.0054 0.0005 1.1138 
Se62 – H80 0.0081 0.0259 –0.0042 0.0053 0.0011 1.2660 
Se60 – H80 0.0138 0.0444 –0.0080 0.0095 0.0015 1.1936 
Se61 – H79 0.0092 0.0296 –0.0046 0.0060 0.0013 1.2928 
Se61 – H78 0.0078 0.0237 –0.0034 0.0046 0.0012 1.3567 
Intermolecular hydrogen bonds 
O21 – H75 0.0494 0.1658 –0.0421 0.0417 –0.0003 0.9920 
H30 – O71 0.0277 0.0891 –0.0217 0.0220 0.0002 1.0114 
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